Destruction of human immunodeficiency-infected cells by ferrofluid particles manipulated by an external magnetic field: Mechanical disruption and selective introduction of cytotoxic or antiretroviral substances into target cells

Medical Hypotheses

Volumn 46, Issue 1, 1996, Pages 5-12

  Peasley, K W ^a  

^a Box 127 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIRETROVIRUS AGENT; CLADRIBINE; CYTARABINE; CYTOTOXIC AGENT; FLUDARABINE; FLUOROURACIL; MANNITOL; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; NEOMYCIN; NUCLEOSIDE ANALOG; OLIGONUCLEOTIDE;

DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAGNETIC FIELD; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS CELL INTERACTION;

EID: 0030070859     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(96)90226-1     Document Type: Article

References (51)

1. Essex M, Kanki PJ. Human immunodeficiency virus type 2 (HIV). In: Broder S, Merrigan Jr T C, Bolognesi D, eds. Textbook of AIDS Medicine. Baltimore: Williams & Wilkins, 1994: 875-876.
2. Palmer E, Goldsmith C S. Ultrastructure of human retroviruses. J Electron Microsc Tech 1988; 8: 3-15.
3. Weiss R A. The virus and its target cells. In: Broder S, Merrigan Jr TC, Bolognesi D, eds. Textbook of AIDS Medicine. Baltimore: Williams & Wilkins, 1994: 15-39.
4. Gelderblom J R. Assembly and morphology of HIV: potential effect of structure on viral function. AIDS 1991; 5: 617-638.
5. Young J A T. The replication cycle of HIV-1. In: Cohen PT, Sande M A, Volberding P A, eds. The AIDS Knowledge Base, 2nd ed. Boston: Little, Brown 1994: 3.1-1-3.1-7.
6. Doweiko J P, Groopman J E. Hematological consequences of HIV infections. In: Broder S, Merrigan Jr T C, Bolognesi D, eds. Textbook of AIDS Medicine. Baltimore: Williams & Wilkins, 1994: 617-626.
7. Embretson J, Zupancic M, Ribas J L, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362: 359-62.
8. Frankel A D, Feinberg M B. Regulation of HIV-1 gene expression. In: Cohen P T, Sande M A, Volberding P A, eds. The AIDS Knowledge Base, 2nd ed. Boston: Little Brown 1994: 3.1-3.3-9.
9. Rosenweig R E. Magnetic fluids. Sci Am 1982, Oct: 136-145.
10. Phillips J B, Borland S C. Use of a specialized magnetoreception system for homing by the eastern red-spotted newt, notophthalmus viridescens. J Exp Biol 1994; 188: 275-291.
11. Arendse MC. Magnetic field detection is distinct from light detection in the invertebrates tenebrio and tailitrus. Nature 1978; 274: 358-362.
12. Beason R C. Use of an inclination compass during migratory orientation by the bobolink (dolichonyx oryzorus). Ethology 1989; 81: 291-299.
13. Keeton W T, Larkin T S, Windsor D M. Normal fluctuations in the earth's magnetic field influence pigeon orientation. J Comp Physiol 1974; 95: 95-103.
14. Kirschvink J L, Jones D S, MacFadden B J. Magnetite Biomineralization and Magnetoreception in Organisms: A New Biomagnetism. New York: Plenum 1984.
15. Walker M M, Quinn T P, Kirschvink J L, Groot C. Production of single-domain magnetite throughout life by sockeye salmon, oncorhynchus nerka. J Exp Biol 1988; 140: 51-63.
16. Kirschvink J L. The horizontal magnetic dance of the honeybee is compatible with a single-domain ferromagnetic compass receptor. Biosystems 1981; 14: 193-203.
17. Kirschvink J L, Walker M M, Chang S B, Dizon A E, Peterson K A. Chains of single-domain magnetite particles in the chinook salmon, oncorhynchus tshawytscha. J Comp Physiol 1985; 157: 375-381.
18. Mann S, Sparks NH, Walker MM, Kirschvink J L. Ultrastructure, morphology, and organization of biogenic magnetite from sockeye salmon, onchorhynchus nerka: implications for magnetoreception. J Exp Biol 1988; 140: 35-49.
19. Perry A, Bauer G B, Dizon A E. Magnetoreception and biomineralization of magnetite in amphibians and reptiles. In: Kirschvink J L, Jones D S, MacFadden, eds. Magnetite Biomineralization in Organisms: A New Biomagnetism. New York: Plenum 1984: 439-453.
20. Walker M M. Learned magnetic field discrimination in yellow-fin tuna, thunnus albacares. J Comp Physiol 1984; 155: 673-679.
21. Yorke, ED. Sensitivity of pigeons to small magnetic field variations. J Theor Biol 1981; 89: 533-537.
22. Jones D S, MacFadden B J. Induced magnetization in the monarch butterfly, danaus plexippus (insecta lepidotrera). J Exp Biol 1982; 96: 1-9.
23. Hanson M, Wirmark G, Oblad M, Strid L. Iron-rich particles in European eel (anguilla anguilla 1). Comp Biochem Physiol 1984; 79A: 311-316.
24. Kirschvink J L, Gould J L. Biogenic magnetite as a basis for magnetic field detection in animals. Biosystems 1985; 13: 181-201.
25. Kirschvink J L, Walker M M. Particle-size considerations for magnetite-based magnetoreceptors. In: Kirschvink J L, Jones D S, MacFadden B J, eds. Magnetite Biomineralization and Magnetoreception in Organisms: A New Biomagnetism. New York: Plenum 1984.
26. Magin R L, Bacic G, Nieesman M R, Alameda Jr J C, Wright S M, Swartz H M. Dextran magnetite as a liver contrast agent. Magnetic resonance in medicine 1991; 20: 1-16.
27. Cerdan S, Lotscher H R, Kunnecke B, Seelig J. Monoclonal antibody-coated magnetite particles as contrast agents in magnetic resonance imaging of tumors. Magnet Reson Med 1989; 12: 151-163.
28. Weiner I M. Diuretics and other agents employed in the mobilization of edema fluid. In: Gilman A G, Rail T W, Nies A S, et al, eds. Goodman and Oilman's The Pharmacological Basis of Therapeutics, 8th ed. New York: Pergamon 1990; 714-715.
29. Cohen J S, Hogan M E. The new genetic medicines. Sci Am 1994, Dec: 76-82.
30. Palu G, Stefanelli S, Rassu M, Parolin C, Balzarini J, DeClercq E. Cellular uptake of phosphonylmethoxyalkylpurine derivatives. Anitviral Res 1991; 15: 116-119.
31. Giovannangeli C, Thuong NT, Helene C. Oligodeoxynucleotide-directed photo-induced cross-linking of HIV proviral DNA via triple-helix formation. Nucleic Acids Res 1992; 20: 4275-4281.
32. Douglas Jr R G. Antimicrobial agents-antiviral agents. In: Gilman A G, Rail T W, Nies A S, et al, eds. Goodman and Oilman's The Pharmacological Basis of Therapeutics, 8th ed. New York: Pergamon 1990: 1182-1201.
33. Calabresi P, Chabner B A. Antineoplastic agents. In: Gilman A G, Rail T W, Nies A S, et al, eds. Goodman's and Oilman's The Pharmacological Basis of Therapeutics, 8th ed. New York: Pergamon 1990: 1209-1257.
34. Yong-su Z, Lui M S, Weber G. Effects of acivicin and dipyridamole on hepatoma 3924a cells. Cancer Res 1983; 43: 1616-1619.
35. Paterson A R P, Kolassa N, Cass C E. Transport of nucleoside drugs in animals cells. Pharmacol Ther Part A Chemother Toxicol Inhibitors 1991; 12: 515-536.
36. Paterson A R P, Lau E Y, Dahlig E, et al. A common basis for inhibition of nucleoside transport by dipyridamole and nitrobenzylthioinosine? Mol Pharmacol 1981; 18: 40-44.
37. Phagemman P G W, Wohlhueter R M. Permeation of nucleosides, nucleic acid bases, and nucleotides in animal cells. Curr Top Member Transp 1980; 12: 225-330.
38. Grem J L, Fischer P H. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res 1985; 45: 2967-2972.
39. Grem J L, Fischer P H. Alteration of fluorouracil metabolism in human colan cancer dells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels. Cancer Res 1986; 46: 6191-6199.
40. Colorectal cancer. Advanced colorectal cancer meta-analyses project. J Clin Oncol 1994; 12: 960.
41. Balzarini J, Naesens I, De Clercq E. Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl) adenine (PMEA) in vivo increases when it is less frequently administered. Int J Cancer 1990; 46: 337-340.
42. Naesens L, Balzarini J, De Clercq E. Single-dose administration of 9-(2-phosphonylmethoxyethyl) adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2, 6 diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Res 1991; 16: 53-64.
43. Balzarini J, Hao Z, Herdewijn P, Johns D G, De Clercq E. Intracellular metabolism and mechanism of antiretrovirus action of 9-(2-phosphonylmethoxyethyl) adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci USA 1991; 88: 1499-1503.
44. Connolly L, Jenkins M. Strategies for antiviral therapy based on the retroviral life cycle. In: Coheb P T, Sande M A, Volberding PA, eds. The AIDS Knowledge Base, 2nd ed. Boston: Little Brown 1994: 3.5-8.
45. Sande M A, Mandell G L. Antimicrobial agents-the aminoglycosides. In: Gilman A G, Rail T W, Nies A S, et al, eds. Goodman and Gileman's The Pharmacological Basis of Therapeutics, 8th ed. New York: Pergamon 1990: 1098-1112.
46. Baba M, Schols D, De C E, et al. Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation. Antimicrob Agents Chemother 1990; 34: 134-138.
47. Schols D, Pauwels R, Desmyler L, et al. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology 1990; 175: 556-561.
48. Erickson C C, Bradley M O, Ducore J M, et al. DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosourea. Proc Natl Acad Sci USA 1980; 77: 467.
49. Ewig RAG, Kohn K W. DNA damage and repair of mouse leukemia L1210 cells treated with nitrogen mustard 1,3-bis (w-cholorehtyI)-1-nitrosourea, and other nirtosoureas. Cancer Res 1977; 37: 2114.
50. Begleiter A, Lam H-Y P, Grover J, et al. Evidence for active transport of melphalan by two amino acids carriers in L5178Y lymphblasts in vitro. Cancer Res 1979; 39: 353.
51. Vistica D T, Toal J N, Rabinowitz M. Amino acid conferred protection against malphalan. Characterization of melphalan transport and correlation of uptake with cytotoxicity in cultured L1210 murine leukemia cells. Biochem Pharmacol 1978; 27: 2865.